clinical trial · NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Janssen Research & Development, LLC·phase3·recruiting·n = 641
Non-Muscle Invasive Bladder NeoplasmsTAR-210GemcitabineMMC
brief summary
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
started
Apr 18, 2024
primary completion
Jun 28, 2028
completion
Dec 31, 2032
last updated
Apr 13, 2026
official title
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol